Contact Dr. Taub at (303) 249-9174 or by email
Historical Review
==========
2008 to present, Chief Medical Officer, OTraces, Inc.
OTraces is doing the clinical testing of blood based screening tests for cancer. Initial data indicate breast, prostate and lung cancer can be detected with a sensitivity and specificity in excess of 90% -95% by analyzing serum. These tests are expected to first supplement and then frequently replace the older less sensitive and less specific screening methods. The sensitivity and specificity of current screening including mammography, PSA and chest x-ray is much lower. For example at the current standard cut off (4 ng/ml) the sensitivity of PSA for prostate cancer is only 21%.
2007 CEO of CytoCore, Inc. (CYOE)
Developer of diagnostic and therapeutic products for genitourinary cancers.
2005-Present: Founder & Director of CureImmune Corporation.
CureImmune is a developer of scientifically proven OTC immune modulating therapies
1999-Present: Founder of LifeTime™ Pharmaceuticals Inc.
LifeTime™ is a clinical-stage pharmaceutical company focused on "fast tracked" small molecules designed to treat life-threatening diseases.
1997-Present: Founder FindCure.Org ( previously Victory Over Cancer and Chronic Conditions). FindCure is a non-profit organization committed to stimulate clinical development of non-toxic agents that can modulate the immune system to better fight cancer, in people and in pets. The Foundation’s motto is “Developing and Distributing New Therapies”. The focus includes lymphoma, myeloma, brain and colon cancer and other diseases in which immune systems stimulation may help. It provides free therapy to those in need.
1994-2005: Founder and Chairman of Dovetail Technologies Inc. DTI is, leading a paradigm shift by identifying and applying drugs 1 thousand to 1 million-fold more potent than conventional drugs. This Nanodrug™ technology offers ultra high potency, ultra low toxicity and virtually side effect free therapy. It reduces frequency of administration for easier and more effective patient compliance and lower cost. Dovetail engaged in research, development and commercialization of cutting edge, patented, immuno-therapeutic technologies for illnesses including cancer, hepatitis, HIV, allergies, fatigue, flu and the common cold.
Main Accomplishments
- Brought Lead Drug product to market without major outside capitalization
- Developed the technology used by LifeTime Pharmaceuticals, Inc
Dovetail’s first products, each containing Taurox™ and other ingredients were labeled for the treatment of fatigue and allergies, cold and flu. It reduced fatigue by optimizing the immune system. These products reached the market six months ahead of plan due to achieving statistically significant effects in patients with cancer, hepatitis and chronic fatigue syndrome very rapidly. Over 90% of patients experience a reduction in fatigue in clinical trials. Symptoms are typically reduced 50-66%. The product is now sold nationwide through a variety of marketing arrangements. Post marketing analysis confirms the commercial preparation has the same activities as seen in the clinical trials. The overwhelming majority of patients respond and it allows some debilitated patients to return to normal activities.
1984 -1990: Founder, CEO, President and V.P. of Research and Development, Digene Diagnostics, Inc. Guided corporate development and technical R&D during the organizations growth from 1 to 50 employees. Digene developed reagents for and clinical methods for using diagnostic DNA techniques.
Main accomplishment: Identified the need for and then conceived, designed, developed, and marketed diagnostic tests to help prevent either under treatment or unnecessary surgical treatment that results from the frequently inaccurate "PAP" smear. Digene’s tests distinguish those abnormalities which contain types of papilloma virus (HPV) of the type that cause cancer from identical appearing abnormalities which are not pre-cancerous since they do not contain oncogenic papilloma viruses. Digene still (May 2006) is the only provider of a FDA approved diagnostic for HPV typing. It has been approved as part of routine screening and has become the standard of optimal care.
Additional accomplishments at Digene:
- Raised over seven (7) million dollars.
- Negotiated a corporate partnership with Mitsubishi Petrochemical Company, Ltd., to fund R&D and to distribute Digene’s products in Japan. This arrangement retained all Digene's technology and product manufacture rights and specified "flowback" for Mitsubishi technology and products in the DNA field.
- Conceived, wrote, and executed research grants and contracts in excess of $1.3 million under the federal Small Business Innovative Research (SBIR) program. Achieved 100% success rate on Phase II applications and in completion of major project goals.
- Marketed a line of molecular biology reagents, services, and DNA probe tests. Sixteen DNA probe kits were developed.
- Designed and outfitted 3 facilities, including a 9,500 sq. ft. R+D facility built to specifications and a 10,000 sq. ft. manufacturing facility.
- Authored six patent applications and numerous disclosures in DNA probes, molecular biology and diagnostic medicine.
- Qualified DDI as the first biotechnology company to be admitted to the University of Maryland Technology Advancement Program and subsequently qualified Digene to be a "jump start" (rapid sales growth) company, as evaluated by Washington High Technology.
1982-1984: Head, Pathology Unit, Laboratory of Oral Medicine (Chief: Abner Notkins, M.D.) National Institute of Dental Research, and National Institutes of Health, Bethesda, MD. The unit specialized in the use of human monoclonal antibodies (derived by hybridoma technology and EBV transformation) in pathology and in the study of autoimmunity. Several of these antibodies were evaluated as clinical diagnostic tools for detecting and evaluating cancers. Research and clinical assays of autoimmunity in diabetes were developed.
1981-1982: First Surgical Pathology Fellow at George Washington University (Head, Anatomic Pathology: Steven Silverberg, M.D.). Served as "Attending Pathologist."
1978-1981: Research Associate, National Cancer Institute, Laboratory of Biochemistry (Chiefs: Robert Goldberger, M.D., and Maxine Singer, Ph.D.), Biochemistry of Gene Expression Section (Head: E. Brad Thompson). Studies on the control of glucocorticoid inducible genes. The methods used included recombinant DNA technology, somatic cell hybridizations, enzyme purification, antibody production, and solution and filter hybridization of nucleic acids. This work included differential screening of a rat liver cDNA library to directly identify clones containing glucocorticoid-induced or -repressed RNA sequences.
Developed a unique system using computerized image processing, enhancement, and quantification to evaluate gene expression (Genomics) via solution-solid phase hybridization to each member of a cDNA library. This technology allowed detailed study of gene regulation and isolation of specific recombinant clones. This new system is the nucleic acid counterpart of comparative two-dimensional protein gel electrophoresis.
1976-1978: Autopsy Supervisor, University of Colorado Medical Center. Designed the program and was responsible for supervising the autopsy-related work of up to 12 physicians. Favorable evaluation led to the program's continuation after his tenure at UCMC ended.
Research with Paul Nakane, Ph.D., Pathology Department, University of Colorado Medical Center. Differentiation of pituitary cells following endocrine manipulation in vivo was studied. Techniques used included multiple peroxidase-labeled anti-hormone antibodies and flow microfluorometry.
1974-1976: Research with Terry Johnson, Ph.D., Department of Microbiology, Northwestern University Medical School. (Dr. Johnson is now Professor/Director of the Division of Biology, Kansas State University.) A model system for pediatric brain damage in the genetic disease phenylketonuria (PKU) was examined. Nucleic acid and protein biochemistry defined the molecular site of inhibition of protein synthesis in immature rat brain following phenylalanine overloading. Based on this work, a new therapeutic approach was devised. This approach was effective in an animal model of PKU.
1971: National Science Foundation Research Participation Program Grantee for work with Aryeh Routtenberg, Ph.D., at Northwestern University Psychology Department. A novel method for determination and documentation of functional relationships between structurally diverse CNS regions was devised.
1968-1969: Research and study under Rulon Rawson, M.D., Vice President and Dean, New Jersey College of Medicine and Dentistry. In vivo studies of induction of red blood cell production by erythropoietin (epo) following radiation injury were performed. This work led to a Special Army Science Award. Epo class drugs have a market of over $5 billion and for many years been the best selling biotechnology drugs. The are used to treat fatigue. However unlike the drugs Dr. Taub has recently developed their use is limited to those with anemia.
Representative Invited Presentations:
Societies (not all current):
Historic Review of Medical Training
1970-1976 |
Entered Northwestern University's Honor Program in Medical Education directly from high school. 1974, B.S. 1976, M.D. |
1975 |
Commissioned Jr. Assistant Surgeon, United States Public Health Service. |
1976-1978 |
Anatomic pathology internship and residency, University of Colorado Medical Center. Subspecialty: endocrine pathology. Training included ultrastructural, immunohistochemical, surgical, and autopsy pathology. Autopsy supervisor, January to June, 1978. |
1980 |
Promoted to Full Surgeon, United States Public Health Service. |
1981-1982 |
Surgical Pathology Fellow, George Washington University. |
1982 |
Diplomat of the American Board of Pathology. |
Current licenses to practice medicine in Maryland and California.
More than 50 publications in scientific literature. Inventor or co-inventor on seven biomedical patents/applications.